Persistence With Lipid-Lowering Therapy: Influence of the Type of Lipid-Lowering Agent and Drug Benefit Plan Option in Elderly Patients
Open Access
- 1 September 2004
- journal article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 10 (5) , 404-411
- https://doi.org/10.18553/jmcp.2004.10.5.404
Abstract
OBJECTIVE: To determine the effects of lipid-lowering agent (LLA) class and drug plan design option on persistence with LLAs among elderly patients enrolled in a managed care plan. METHODS: A retrospective cohort study was conducted among 310 older adult members enrolled in a health maintenance organization operating in New England who were dispensed an LLA between July 1, 1994, and June 30, 1996. Survival analysis was used to examine differences in discontinuation of LLAs between different classes of LLAs and drug benefit plans as well as patient sex, age, prior hospitalization for coronary heart disease (CHD), hypertension, diabetes mellitus, and the number of other medications. RESULTS: The overall LLA discontinuation rate increased with time from 18% (95% confidence interval [CI], 13.8%-22.4%) at 6 months to 46% (95% CI, 39.7%-52.5%) at 12 months and 66% (95% CI, 59.2%-73.0%) at 18 months. The likelihood of discontinuation increased from 54% (95% CI, 44.8%-63.6%) at 12 months to 77% (95% CI, 67.5%-85....Keywords
This publication has 0 references indexed in Scilit: